Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

arges of $5.9 million in 2009 and $4.1 million in 2008; (4) Kuvan approval milestones received of $31.5 million earned in 2008; (5) the gross margin of the initial Aldurazyme product transfer to Genzyme of $2.3 million associated with the restructuring of BioMarin/Genzyme LLC in the first quarter of 2008; (6) gain on the sale of equity investments of $1.6 million in 2009 and (7) income tax effect of $0.3 million and $2.2 million in 2009 and 2008, respectively. The reconciliation of these measures to the estimated GAAP net income is detailed in the table provided at the end of the press release.

BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan and Aldurazyme and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future. Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Diluted Earnings Per Share Calculation

The calculation of GAAP diluted earnings per share for all of the 2009 periods presented and non-GAAP diluted earnings per share for the third quarter and first nine months of 2008 reflect the theoretical exclusion of the interest expense from net earnings that would no longer be incurred if the Company's convertible notes were converted into shares as their impact is considered anti-dilutive. Non-GAAP diluted earnings per share for the third quarter and first nine months of 2009 include 16.0 million shares related to the Company's convertible notes due in April 2017
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... ATLANTA, Feb. 10 Food retailers concerned about pathogens ... coli in their perishable departments can now outsource ... operates food safety and sanitation programs throughout the United ... food safety, Chemstar has expanded its sanitation services to ...
... Recent clinical data show that Restylane (R) lasted 18 ... Restylane (R) is the only ... data were generated in a controlled, randomized, evaluator-blinded study that ... 4.5 months or 9 months, after initial treatment of nasolabial ...
Cached Medicine Technology:Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets 2Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection 2
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... discovering a new mechanism that allows blood to enter ... Irvine and the Salk Institute have opened the door ... brain damage. , A complex and devastating neurological condition, ... reason for disability in the U.S. The blood-brain barrier ... material into the brain, causing the permanent deficits in ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... announces that the Journal of the American Society of ... in MEDLINE. MEDLINE is the premier bibliographic database of the ... journal article citations, with a concentration on biomedicine. "The ... JASH has been added to the MEDLINE journal collection," ...
... will discuss the impact of health information technology on ... symposium at 1 p.m. PT Friday, Oct. 1, as ... American Academy of Pediatrics (AAP) in San Francisco. ... Health Information Technology (HIT) in the U.S. Department of ...
... the Journal of Thoracic Oncology (JTO), data ... the safety and efficacy profile of erlotinib, a highly ... receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous ... has been shown to significantly increase survival for patients ...
... by University of California, San Diego researchers 14 years earlier, ... with just enough sleep. Less than five hours a night ... A team of scientists, headed by Daniel F. Kripke, ... of Medicine, revisited original research conducted between 1995 and 1999. ...
... Mass. -- MIT researchers and collaborators from Tufts University have ... a critical compound that is a precursor to the cancer ... yew tree. The tree,s bacteria can produce 1,000 times more ... microbial strain. The technique, described in the Oct. 1 ...
... By Kathleen Doheny HealthDay Reporter , THURSDAY, ... infertility often escapes experts, but scientists have found a ... "This may be the most frequent single gene ... date, with 4 percent of men with unexplained severe ...
Cached Medicine News:Health News:JASH accepted for coverage in MEDLINE 2Health News:TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer 2Health News:Women's study finds longevity means getting just enough sleep 2Health News:Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol 2Health News:Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol 3Health News:Genetic Glitch Tied to Disrupted Sperm Production 2
... Easy-On Knee Brace features an adjustable ... 0to 135 in 10 increments. Adjust ... to expose the stop pins and ... thick, self-padded washable fabric with Velcro ...
... Aircast Patellar Brace is a support designed ... shaped aircell stabilizes the patella and compresses ... position of the patella. During ambulation, the ... reduce swelling and pain. A moveable aircell ...
... the therapeutic benefits of controlled compression to minimize ... The cuff is anatomically designed to completely fit ... is available in three sizes for adults and ... for children 1 - 7 years of age. ...
Unique supportive clavicle splint. Features front closure design for convenience in application. Comfortable padding over clavicle area....
Medicine Products: